ES2257817T3 - Metodos y composiciones para terapias contra el cancer utilizando genes codificantes de interferon-beta. - Google Patents

Metodos y composiciones para terapias contra el cancer utilizando genes codificantes de interferon-beta.

Info

Publication number
ES2257817T3
ES2257817T3 ES98944526T ES98944526T ES2257817T3 ES 2257817 T3 ES2257817 T3 ES 2257817T3 ES 98944526 T ES98944526 T ES 98944526T ES 98944526 T ES98944526 T ES 98944526T ES 2257817 T3 ES2257817 T3 ES 2257817T3
Authority
ES
Spain
Prior art keywords
interferon
cells
vector
gene
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98944526T
Other languages
English (en)
Spanish (es)
Inventor
James G. Barsoum
Xiao-Qiang Qin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ES2257817T3 publication Critical patent/ES2257817T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES98944526T 1997-08-29 1998-08-25 Metodos y composiciones para terapias contra el cancer utilizando genes codificantes de interferon-beta. Expired - Lifetime ES2257817T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
US57254P 1997-08-29

Publications (1)

Publication Number Publication Date
ES2257817T3 true ES2257817T3 (es) 2006-08-01

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98944526T Expired - Lifetime ES2257817T3 (es) 1997-08-29 1998-08-25 Metodos y composiciones para terapias contra el cancer utilizando genes codificantes de interferon-beta.

Country Status (24)

Country Link
EP (1) EP1007717B8 (enExample)
JP (3) JP4124565B2 (enExample)
KR (1) KR100699285B1 (enExample)
CN (1) CN100342019C (enExample)
AT (1) ATE316145T1 (enExample)
AU (1) AU740428B2 (enExample)
BR (1) BR9812138A (enExample)
CA (1) CA2300480C (enExample)
CY (1) CY1105029T1 (enExample)
CZ (2) CZ297314B6 (enExample)
DE (1) DE69833264T2 (enExample)
DK (1) DK1007717T3 (enExample)
EA (1) EA003256B1 (enExample)
EE (1) EE04873B1 (enExample)
ES (1) ES2257817T3 (enExample)
HU (1) HU224422B1 (enExample)
IL (2) IL134593A0 (enExample)
IS (1) IS2318B (enExample)
NO (1) NO20000990L (enExample)
NZ (1) NZ503401A (enExample)
PT (1) PT1007717E (enExample)
SK (1) SK286821B6 (enExample)
TR (1) TR200000532T2 (enExample)
WO (1) WO1999010516A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363676B1 (en) * 2001-01-22 2007-03-28 Biogen Idec MA Inc. Method of enhancing delivery of a therapeutic nucleic acid
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
CN114630670B (zh) * 2019-06-01 2025-03-11 西韦克生物技术有限责任公司 用于将基因编辑系统递送至真核细胞的细菌平台

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US6204052B1 (en) * 1994-08-16 2001-03-20 Introgene B.V. Adenoviral vectors with reduced TNF response and partial E3 region deletion
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
TR200000532T2 (tr) 2000-11-21
AU740428B2 (en) 2001-11-01
HK1029599A1 (en) 2001-04-06
IS2318B (is) 2007-11-15
NZ503401A (en) 2003-01-31
HUP0002913A3 (en) 2003-08-28
CN100342019C (zh) 2007-10-10
EP1007717B1 (en) 2006-01-18
IL134593A0 (en) 2001-04-30
IL134593A (en) 2007-06-17
JP2005225888A (ja) 2005-08-25
NO20000990D0 (no) 2000-02-28
CA2300480C (en) 2010-01-05
CA2300480A1 (en) 1999-03-04
KR100699285B1 (ko) 2007-03-26
BR9812138A (pt) 2000-07-18
JP4219335B2 (ja) 2009-02-04
DE69833264D1 (de) 2006-04-06
WO1999010516A2 (en) 1999-03-04
EE04873B1 (et) 2007-08-15
DE69833264T2 (de) 2006-09-28
ATE316145T1 (de) 2006-02-15
PT1007717E (pt) 2006-06-30
IS5374A (is) 2000-02-11
CN1271391A (zh) 2000-10-25
EA003256B1 (ru) 2003-02-27
SK286821B6 (sk) 2009-06-05
KR20010023511A (ko) 2001-03-26
AU9205198A (en) 1999-03-16
HU224422B1 (hu) 2005-08-29
JP2004155786A (ja) 2004-06-03
CY1105029T1 (el) 2010-03-03
WO1999010516A3 (en) 1999-05-06
EE200000102A (et) 2000-12-15
CZ2000733A3 (cs) 2000-06-14
EP1007717A2 (en) 2000-06-14
JP4124565B2 (ja) 2008-07-23
HUP0002913A2 (hu) 2000-12-28
JP2001514010A (ja) 2001-09-11
JP3953458B2 (ja) 2007-08-08
EA200000270A1 (ru) 2000-10-30
EP1007717B8 (en) 2006-05-03
CZ299095B6 (cs) 2008-04-23
NO20000990L (no) 2000-05-02
CZ297314B6 (cs) 2006-11-15
DK1007717T3 (da) 2006-05-29
SK2482000A3 (en) 2000-08-14

Similar Documents

Publication Publication Date Title
ES2264145T3 (es) Metodos y composiciones para el tratamiento de cancer.
ES2298174T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
US9439977B2 (en) Methods and compositions for treatment of interferon-resistant tumors
PL186073B1 (pl) Preparat farmaceutyczny, zwłaszcza do terapii genowej
ES2257817T3 (es) Metodos y composiciones para terapias contra el cancer utilizando genes codificantes de interferon-beta.
US6696423B1 (en) Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US7163925B1 (en) p16 expression constructs and their application in cancer therapy
EP1679375A1 (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
MXPA00002101A (es) Metodos y composiciones para terapias que utilizan genes que codifican proteinas secretadas como beta-interferon
HK1029599B (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
HK1095356A (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
Mazzolini et al. The promise of gene therapy in gastrointestinal and liver diseases
HK1095525B (en) Methods and compositions for treatment of interferon-resistant tumors